Theravance Biopharma, Inc. · NASDAQ:TBPH

Theravance Biopharma — Investor Presentation (January 2022)

15 slides from Theravance Biopharma's investor presentation, Jan 10, 2022

  1. Slide 1: Appendix Slides to Investor Presentation January 2022

    THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ©

  2. Slide 2: Forward-looking statements safe harbor

    Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from th

  3. Slide 3: COPD and Asthma Background

    COPD and Asthma Background

  4. Slide 4: COPD is characterized by persistent airflow limitation that is not fully reversible

    COPD is characterized by persistent airflow limitation that is not fully reversible ‣ Progressive, partially irreversible airway damage – Chronic bronchitis: Chronic inflammation of bronchi with mucus hypersecretion, leading to airway narrowing and obstruction of airflow – Emphysema: Destruction of

  5. Slide 5: Three classes of inhaled medicines form backbone of long-term maintenance therapy

    Three classes of inhaled medicines form backbone of long - term maintenance therapy for both COPD and asthma Class Mechanism of Action Key Brands* (Mfg., 2020 Global Net Sales) LABA Long - acting beta agonists Activate beta 2 - adrenergic receptors to reduce free intracellular calcium, thereby relax

  6. Slide 6: Dual combinations and triple combinations have become market leaders

    'XDO FRPELQDWLRQV DQG PRUH UHFHQWO\ WULSOH FRPELQDWLRQV KDYH EHFRPH PDUNHW OHDGHUV Dual Combinations Key Brands (Mfg., 2020 Global Net Sales) ICS / LABA Indicated for both COPD & asthma Symbicort (AZ, $2.7 B) Advair (GSK, $2.0 B) Breo (GSK, $1.4 B) Generics ($930 M) LABA / LAMA Indicated only for CO

  7. Slide 7: Overview of nebulized products for maintenance therapy

    2YHUYLHZ RI QHEXOL]HG SURGXFWV IRU PDLQWHQDQFH WKHUDS\ Nebulizers provide a user - friendly option for providers and their COPD patients : ‣ Require only normal tidal breathing and do not require extra effort generating adequate inspiratory flow rate ‣ No hand - breath coordination is needed ‣ Many

  8. Slide 8: FDA-approved for the maintenance treatment of COPD

    FDA - approved for the maintenance treatment of COPD First and only once - daily, LAMA (long - acting muscarinic agent) nebulized maintenance medicine for COPD

  9. Slide 9: YUPELRI is the first and only once-daily, nebulized maintenance medicine for COPD

    YUPELRI ® ( revefenacin ) is the first and only once - daily, nebulized maintenance medicine for COPD COPD, chronic obstructive pulmonary disease; LABA, long - acting beta 2 agonists; LAMA, long - acting muscarinic antagonist; PIFR, peak inspiratory flow rate. 9 Companies co - promote under US profi

  10. Slide 10: Despite impact, YUPELRI sales still increasing

    9.1 16.5 29.6 36.8 30.3 37.0 38.7 36.9 41.8 39.4 COVID - 19 placed unprecedented demands on pulmonologists COVID - 19 outbreak coincided with critical period of YUPELRI ® launch Where the market has been 1. Source: SHA METYS through Q3’21 ; 2. Source: IQVIA DDD through Sep’21. 2. COPD, chronic obstr

  11. Slide 11: YUPELRI more likely to be added to Neb LABA than be a conversion

    YUPELRI ® more likely to be added to Neb LABA than be a conversion from long - acting Neb competitors ‣ Budesonide (ICS), Perforomist and Brovana are the products most often used in combination with YUPELRI – 40 – 50% of YUPELRI patients are also on Neb LABA – 35 – 40% of YUPELRI patients are on ope

  12. Slide 12: Data sources for tracking YUPELRI volume

    ‣ Shipments from wholesalers to outlets; Does not include filled Rxs ‣ Outlet sub - categories allow for distinction between inpatient and outpatient entities ‣ Additional hospital volume in VA and outlets that do not report to DDD ‣ Majority of YUPELRI business flows through the DME channel ‣ Data

  13. Slide 13: Educating health-care providers via publications

    Educating health - care providers via publications 1. Tashkin DP, Barjaktarevic IZ. Chronic Obstr Pulm Dis 2020;7:136 - 8. 2. Hess MW. Int J Chron Obstruct Pulmon Dis 2020;15:2101 - 2. 3. Woods JA. J Am Pharm Assoc 2021;61:e55 - 6. 4. Sethi S, et al. Ther Adv Respir Dis 2020;14:1753466620954366. AGI

  14. Slide 14: About YUPELRI (revefenacin) inhalation solution

    About YUPELRI ® ( revefenacin ) inhalation solution YUPELRI ® ( revefenacin ) inhalation solution is a once - daily nebulized LAMA approved for the maintenance treatment of COPD in the US . Market research by Theravance Biopharma indicates approximately 9 % of the treated COPD patients in the US use

  15. Slide 15: YUPELRI indication and Important Safety Information

    YUPELRI ® ( revefenacin ) inhalation solution YUPELRI ® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . Important Safety Information (US) YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any

Theravance Biopharma — Investor Presentation (January 2022) on 6ix